ArticleCase reports in infectious diseases2024
Evaluation of Neutralizing Capacity of Tixagevimab plus Cilgavimab (AZD7442) against Different SARS-CoV-2 Variants: A Case Report Study with Comparison to a Vaccinated Population.
Constant Gillot et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.